Goldman Sachs Starts AmSurg (AMSG) at Neutral

Goldman Sachs initiated coverage on AmSurg (NASDAQ: AMSG) with a Neutral rating and a price target of $57.

Analyst Brian Zimmerman said, "Our Neutral rating and $57, 12-month price target are based on our view that the improved growth outlook stemming from the recently closed AMSG-Sheridan Healthcare tie-up has largely been priced into the stock. While AMSG is likely to outperform in the ambulatory surgical center (ASC) space, the industry continues to suffer from lackluster organic growth, relying on consolidation to boost numbers. We foresee only moderate near-term improvements in volume and pricing, with growth primarily driven by acquisitions. Layering in Sheridan boosts AMSG’s numbers by expanding service offerings and cross-selling capabilities."

For an analyst ratings summary and ratings history on AmSurg click here. For more ratings news on AmSurg click here.

Shares of AmSurg closed at $53.95 yesterday.

You May Also Be Interested In

• Citi Upgrades United Microelectronics Corp (2303:TT) (UMC) to Buy 'with limited downside'
• Kotak Downgrades 360 ONE WAM Ltd (360ONE:IN) to Add (2)
• DAM Capital Starts Apollo Tyres (APTY:IN) at Buy